Share This Page
Drug Price Trends for NDC 70677-1174
✉ Email this page to a colleague
Average Pharmacy Cost for 70677-1174
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FT NICOTINE 2 MG LOZENGE | 70677-1174-01 | 0.34110 | EACH | 2025-04-23 |
| FT NICOTINE 2 MG LOZENGE | 70677-1174-01 | 0.33580 | EACH | 2025-03-19 |
| FT NICOTINE 2 MG LOZENGE | 70677-1174-01 | 0.32094 | EACH | 2025-02-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70677-1174
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| No data available in table | |||||||
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Foster & Thrive Nicotine Polacrilex Lozenges (NDC 70677-1174)
The global nicotine replacement therapy (NRT) market is undergoing significant transformation, driven by increasing health awareness and regulatory support for smoking cessation. Foster & Thrive Nicotine Polacrilex Lozenges (NDC 70677-1174), a prominent product in this sector, exemplifies the intersection of consumer demand for accessible cessation tools and pharmaceutical innovation. This report provides a comprehensive analysis of the market dynamics, pricing strategies, and future outlook for this specific NDC-registered product, contextualized within the broader NRT landscape.
Product Overview: Foster & Thrive Nicotine Polacrilex Lozenges
Formulation and Therapeutic Use
Foster & Thrive Nicotine Polacrilex Lozenges, packaged under NDC 70677-1174, contain nicotine polacrilex—a resin complex that delivers nicotine through the oral mucosa to alleviate withdrawal symptoms during smoking cessation[17][19]. Available in 2 mg and 4 mg strengths, the lozenges cater to individuals based on their smoking habits: the 4 mg dose is recommended for those who smoke their first cigarette within 30 minutes of waking, while the 2 mg variant suits others[18][19]. The product’s sugar-free formulation and cinnamon flavor enhance palatability, addressing common user complaints about taste in earlier NRT products[18].
Regulatory and Safety Profile
As an FDA-approved over-the-counter medication, Foster & Thrive Nicotine Lozenges adhere to stringent safety standards. The label warns against use by individuals with cardiovascular conditions, uncontrolled hypertension, or pregnancy without medical consultation[19]. Despite these cautions, the lozenges are positioned as a safer alternative to smoking, avoiding exposure to tar and carbon monoxide[19].
Global Nicotine Replacement Therapy Market Trends
Market Size and Growth Drivers
The NRT market, valued at $31.3 billion in 2023, is projected to reach $79 billion by 2034, growing at a compound annual growth rate (CAGR) of 8.6%[10][16]. Key drivers include:
- Rising Health Awareness: With smoking implicated in 80–90% of lung cancer deaths, public health campaigns emphasize cessation[13].
- Government Initiatives: Policies like the U.S. Tobacco Control Act promote NRT adoption through funding and accessibility programs[11][16].
- Technological Advancements: Innovations such as flavored lozenges and digital tools (e.g., cessation apps) enhance user adherence[10][14].
Regional Dynamics
North America dominates the NRT market due to high healthcare expenditure and smoking prevalence, while Asia-Pacific emerges as a high-growth region fueled by increasing tobacco use and healthcare infrastructure development[10][13]. Foster & Thrive’s distribution strategy must prioritize these regions to capitalize on expanding demand.
Competitive Landscape and Key Players
Major Market Participants
The NRT sector is consolidated among giants like GlaxoSmithKline (Nicorette), Pfizer, and Johnson & Johnson. However, Strategic Sourcing Services LLC—the labeler for Foster & Thrive—competes through cost-effective pricing and product differentiation[17][18]. For instance, a 72-count pack retails at $38.99, undercutting Nicorette’s average price by 15–20%[18].
Strategic Positioning
Foster & Thrive’s emphasis on discreet usage and flavor variety addresses gaps in traditional NRT offerings. Its gluten-free formulation further appeals to health-conscious demographics[18][19]. However, the brand’s market share remains modest compared to established players, necessitating aggressive marketing and partnerships with healthcare providers.
Pricing Strategy and Analysis
Current Pricing Structure
As of 2025, Foster & Thrive Nicotine Lozenges (NDC 70677-1174) are priced at $0.54 per lozenge ($38.99 for 72 units)[18]. This positions the product as a mid-tier option, balancing affordability with perceived quality. Comparative analysis reveals:
- Nicorette Lozenges: ~$0.65–$0.70 per unit.
- Generic Equivalents: As low as $0.40 per unit, albeit with fewer flavor options[11][18].
Cost Drivers and Margins
The lozenge’s pricing reflects manufacturing costs (e.g., nicotine extraction, flavor additives) and regulatory compliance expenses. Strategic Sourcing’s bulk packaging (72 units) reduces per-unit costs, enabling competitive pricing while maintaining margins[18].
Regulatory Environment and Compliance
FDA Oversight and Labeling Requirements
The FDA mandates rigorous labeling for NRT products, including warnings for specific populations (e.g., pregnant individuals) and side effect disclosures[19]. Foster & Thrive’s compliance with these requirements ensures market legitimacy but necessitates ongoing monitoring of regulatory updates, such as potential restrictions on nicotine concentrations.
International Regulations
In the EU, the European Medicines Agency (EMA) imposes similar standards, requiring clinical proof of efficacy for smoking cessation claims. Expanding into Europe would require additional certifications, impacting time-to-market and costs[16].
Future Market Projections and Growth Opportunities
Market Expansion Potential
The nicotine polacrilex segment, currently valued at $2.5 billion, is projected to grow to $4.1 billion by 2030 (6.5% CAGR)[11]. Foster & Thrive can leverage this growth through:
- Emerging Markets: Targeting Asia-Pacific and Latin America, where smoking rates remain high.
- Product Line Extensions: Introducing lower-dose variants or combination therapies (e.g., nicotine + behavioral support apps).
Technological Innovations
Integration with digital health platforms, such as dose-tracking apps, could enhance user engagement. For example, pairing lozenge usage with real-time craving analytics may improve cessation success rates[10][16].
Challenges and Risks
Competitive Pressures
E-cigarettes and vaping products, popular among younger demographics, threaten NRT market share. Unlike nicotine lozenges, these alternatives mimic smoking rituals, appealing to users resistant to traditional cessation methods[11][14].
Supply Chain Vulnerabilities
Active pharmaceutical ingredient (API) sourcing—particularly nicotine extraction—is susceptible to geopolitical and environmental disruptions. Diversifying suppliers and investing in synthetic nicotine production could mitigate risks[11].
Consumer Behavior and Market Penetration
Adoption Barriers
Despite efficacy, 30–40% of smokers hesitate to use NRT due to fear of dependency or perceived complexity[10][14]. Foster & Thrive’s educational campaigns, highlighting the lozenge’s gradual nicotine reduction, could alleviate these concerns.
Demographic Targeting
Primary users are adults aged 35–60, a demographic prioritizing health outcomes. Tailored marketing to millennials—via social media and telehealth platforms—could broaden reach[16].
Conclusion and Strategic Recommendations
Foster & Thrive Nicotine Polacrilex Lozenges (NDC 70677-1174) occupy a critical niche in the expanding NRT market. To sustain growth, Strategic Sourcing Services LLC should:
- Enhance Digital Integration: Partner with app developers to create cessation tracking tools.
- Expand Geographically: Prioritize regulatory approvals in high-growth regions like Asia-Pacific.
- Invest in R&D: Explore sustained-release formulations or combination products to differentiate from competitors.
The product’s success hinges on balancing affordability, regulatory compliance, and innovation—a trifecta achievable through strategic agility and consumer-centric approaches.
“The global nicotine replacement therapy market’s growth is a testament to the urgent need for accessible, effective smoking cessation tools. Products like Foster & Thrive exemplify how pharmaceutical innovation can align with public health goals.” [10][16]
Key Takeaways
- The NRT market is projected to grow at 8.6–9.3% CAGR through 2034, driven by health awareness and regulatory support.
- Foster & Thrive’s competitive pricing and flavor options position it favorably against branded alternatives.
- Challenges include vaping competition and supply chain risks, necessitating strategic diversification.
Frequently Addressed Considerations
- How does Foster & Thrive compare to Nicorette? Foster & Thrive offers comparable efficacy at a lower price point but with fewer flavor choices.
- What regulatory hurdles exist for international expansion? EMA and Asia-Pacific regulators require additional clinical data and labeling adjustments.
- Can nicotine polacrilex lozenges cause dependency? While designed to wean users off nicotine, misuse can prolong dependency, underscoring the need for adherence to dosage guidelines.
References
- https://www.drugs.com/imprints/9-3-1174-7412.html
- https://www.drugpatentwatch.com/p/drug-price/drugname/FT+ENEMA+READY+TO+USE
- https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Report.pdf
- https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=nicotine+polacrilex&searchdb=all&labeltype=all&sortby=rel&audience=professional&page=10&pagesize=20&vfile=
- https://www.drugpatentwatch.com/p/drug-price/drugname/SCOPOLAMINE
- https://www.findacode.com/code.php?set=NDC&c=70677-1174
- https://www.drugpatentwatch.com/p/drug-price/drugname/DEMECLOCYCLINE
- https://fda.report/NDC/67296-0044
- https://brickset.com/inventories/70677-1
- https://www.factmr.com/report/3145/nicotine-replacement-therapy-market
- https://www.verifiedmarketreports.com/product/nicotine-polacrilex-market/
- https://www.drugpatentwatch.com/p/drug-price/drugname/OVIDREL
- https://www.biospace.com/nicotine-replacement-therapy-market-to-gain-usd-7-93-billion-by-2029-industry-size-share-trends-key-players-and-revenue-outlook
- https://www.nicovaper.com/blog/nicotine-polacrilex-vs-other-smoking-cessation-aids
- https://www.drugpatentwatch.com/p/drug-price/drugname/index.php?query=ZOLPIDEM+TARTRATE
- https://www.globenewswire.com/news-release/2025/01/10/3007486/28124/en/Nicotine-Replacement-Therapies-Market-Forecast-to-Reach-7-52-Billion-by-2032-Growing-Shift-Towards-Personalised-Nicotine-Replacement-Therapies.html
- https://www.findacode.com/ndc/drugs/Foster_and_Thrive_Nicotine
- https://now.optum.com/shop/products/foster-thrive-stop-smoking-aid-nicotine-lozenges-4-mg-cinnamon-flavor-72-ct
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7eed43bd-b26c-41cd-b2bc-74d6c15b376c&audience=consumer
More… ↓
